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Clopidogrel and Aspirin on Native Coronary Disease S13 postoperative angiograms to quantitatively assess whether the addition of clopidogrel to aspirin inhibits the progression of native CAD or the development of new coronary lesions after CABG.
Methods
The study is a secondary analysis of prospectively collected data in the CASCADE randomized controlled trial, which was a dual-center, double-blind, placebo-controlled trial. Details of the study protocol were previously published. 6, 11 The trial was approved by each institutional research ethics board, and informed patient consent was obtained before enrollment at each center.
Population
In the CASCADE trial, 113 patients who underwent elective CABG with ≥2 SVGs were enrolled at the University of Ottawa Heart Institute (Ottawa, Ontario, Canada) or at Hôpital Laval (Quebec City, Quebec, Canada) from 2006 to 2009. Preoperative coronary angiogram was performed in all patients. Immediately after surgery, patients were randomized either to the aspirin-clopidogrel group, who received aspirin 162 mg plus clopidogrel 75 mg daily, or to the aspirin-placebo group, who received aspirin 162 mg plus placebo daily. Study medications were started on the day of surgery and continued for 12 months in a double-blinded fashion. Among the 113 patients, the present study assessed the progression of native CAD in the 92 patients who underwent postoperative angiogram at the 2 centers 1 year after CABG (Figure) . Patient characteristics are shown in Table 1 .
Patient Follow-Up
Follow-up was performed in clinic at 1, 6, and 12 months after operation and telephone postoperative assessments at 3 and 9 months. Postoperative management was standardized in both groups. All medications were prescribed according to current American College of Cardiology/American Heart Association guidelines and as clinically indicated, including the use of statins, β-blockers, calcium-channel blockers, and angiotensin-converting enzyme inhibitors. Aggressive diabetes mellitus (DM) management and smoking cessation counseling were performed as indicated. 12 One-year follow-up was performed on all 113 patients. Patients (n=92) underwent postoperative angiogram and intravascular ultrasound 12 months after CABG.
Review and Grading of Angiograms
All 92 patients with a full pair of preoperative and postoperative angiograms had their films reviewed and graded, in blinded fashion to treatment, by a minimum of 2 investigator physicians, including ≥1 cardiologist and 1 surgeon (with ≥1 being M.R., A.K., M.L.M., or P.V.). The location and degree of each stenosis were recorded.
Subsequently, 88 of 92 patients (4 preoperative films were missing and the reports were used) had their source images and loops requantified (serially and in blinded fashion to treatment) by 2 new coinvestigators (D.U. and T.A.-A.), with a focus on native CAD. In case of disagreement, the films were reviewed further, and agreement was reached between the investigators. To avoid previously used subjective grading methods, 13, 14 we a priori defined and used a 6 grade system with normal segments (grade 0) and occlusions (grade 5) defined as 0% to 24% and 99% to 100%, respectively, and other cutoff values predefined ≈50%, 75%, and 90%. With this system, each lesion was graded according to its degree of stenosis as follows: grade 0: 0% to 24% stenosis; grade 1: 25% to 37%; grade 2: 38% to 62%; grade 3: 63% to 82%; grade 4: 83% to 98%; grade 5: 99% to 100%. The following segments were not considered for stenosis quantification: (1) segments within 1 cm proximal or distal to the graft anastomosis; (2) poorly visualized segments; (3) segments with preoperative 99% to 100% stenosis; and (4) segments with flow competition with difficulty in assessment, including lack of contrast filling. However, if previously seen proximal side branches disappeared postoperatively or if no contrast was seen for >2 cm where it had been seen preoperatively, the filling defect was considered to represent a new occlusion.
Evolving CAD was defined as a lesion with ≥1 grade change in the severity of stenosis, calculated as the difference between the preoperative and postoperative grade. A worsening lesion was given a positive value and an improving lesion a negative value. A new lesion was defined as ≥25% postoperative stenosis where the stenosis was preoperatively <25%.
We performed analyses for all lesions, as well as for lesions that may limit blood flow to the myocardium, to focus on clinically important lesions. Such lesions possibly limiting blood supply excluded mild lesions (postoperative grade 0 or 1) and included only moderate to severe (grade 2 or higher) lesions in ungrafted branches, lesions distal to an anastomosis site, or sequential proximal stenoses between which there is no graft.
Statistical Analysis
Data were analyzed in IBM SPSS statistics version 21.0 (IBM Corp, Armonk, NY). Continuous data are presented as a mean±SD and categorical variables as a frequency/proportion. Analyses between 2 groups were performed with an unpaired t test or Mann-Whitney U test, as appropriate, for continuous variables. Categorical variables were compared with a Fisher exact test. Because we dealt with multiple lesions per patient, we performed a generalized estimating equation analysis to compare the proportions of new occlusions and the mean grade changes between the treatment groups. We also evaluated the effects of anatomic factors on native CAD by using the generalized estimating equation analysis. For the comparison of mean grade change by treatment group, we combined lesion progression and regression, each with a different sign (+ and −, respectively), to numerically capture negative and positive changes in lesions for each group. All reported P values are 2-sided, and statistical significance was set at P<0.05.
Results

Clinical Events and Follow-Up
Parts of the data under this heading have previously been reported and are represented for clarity. 6 There was no significant difference in preoperative characteristics and 1-year clinical outcomes between the 2 study groups in all the 113 patients, as well as in the 92 patients who underwent postoperative angiograms (Table 1) . 6 During follow-up, 1 patient, who was in the placebo group, died of a new cerebrovascular accident 7 months after surgery. There were 5 myocardial infarctions (aspirin-clopidogrel group versus aspirin-placebo group, 4 versus 1 patient, respectively; P=0.21) and 4 PCIs for 3 patients (1 versus 2 patients, respectively; P=1.0). Of the 4 PCIs, 2 were for worsening native CAD: one was for a circumflex lesion in the aspirinclopidogrel group and the other was for a right coronary artery lesion in the aspirin-placebo group. The other 2 PCIs were on an SVG and on the native left main coronary artery in the study's only patient with 2 occluded SVGs (aspirinplacebo group).
There was no significant difference in the amount of packed red blood cells transfused in the early postoperative period between the 2 groups (aspirin-clopidogrel group; median 0 U; first and third quartile 0 and 0 U; versus aspirin-placebo group; median 0 U; first and third quartile 0 and 1 U; P=0.57) and no significant difference in the incidence of transfusion (aspirin-clopidogrel versus aspirin-placebo groups, 23.2% versus 33.3%; P=0.30). There was no difference in the incidence of late bleeding events between the 2 groups (P=0.72): 1 major nose bleeding, 1 minor bleeding with hematuria, and 2 minor gastrointestinal bleedings with gastric ulcers in the clopidogrel group and no major, 1 minor nose bleeding, and 2 minor gastrointestinal bleedings with gastric ulcers in the placebo group.
At 
Angiographic Outcomes and Progression of Native CAD
At 1 year, the fate of 543 preoperative stenoses and 322 grafts were assessed in 92 patients. Overall graft patency was 95.3% and was equivalent between the 2 study groups (aspirin-clopidogrel versus aspirin-placebo, overall patency: 95.2% versus 95.5%, P=0.90; SVG patency: 94.3% versus 93.2%, respectively; P=0.69).
The details of the 543 preoperative stenoses that were followed to 1-year postoperatively are shown in Table 2 . Of the 543 lesions, there was progression of ≥1 grade in 94 lesions (22%), no grade change in 317 lesions (76%), and regression of ≥1 grade in 9 lesions (2%). Of the remaining 123 lesions, 73 preoperative stenoses were 99% to 100%, 49 were proximal lesions with competitive flow and difficulty in grade assessment, and 1 lesion was near an anastomosis. Furthermore, there were 22 new stenoses and 18 preoperative stenoses that had become occluded by 1 year after CABG. Table 3 summarizes the comparison of the 2 study groups with regard to evolving and new CAD lesions in native coronary arteries. Among the 103 evolving stenoses (94 progres-sion+9 regression), the mean grade change was 1.1±0.9. The mean grade change of the 22 new stenoses (2.5±1.0) was higher than that of the 103 evolving stenoses (P<0.001).The mean grade change of 18 newly occluded lesions (1.8±0.9) was higher than that of the nonoccluded evolving lesions (1.0±0.9; P<0.001).
The incidence of evolving lesions or new lesions was statistically similar (aspirin-clopidogrel versus aspirinplacebo, 70% [32/46] versus 74% [34/46]; P=0.8). Notably, the mean grade change of lesions for evolving or new stenoses was higher in the aspirin-placebo group (1.6±1.1) than in the aspirin-clopidogrel group (1.1±1.0; P=0.013). Furthermore, the proportion of lesions progressing to a new occlusion was higher in the aspirin-placebo group (22% [14/65]) than in the aspirin-clopidogrel group (7% [4/60]; P=0.020). 
Effects in Patients With DM
Impact of Anatomic Factors
The effects of anatomic factors on native CAD progression are summarized in Tables 6 to 8 
Discussion
The main finding in this study was that compared with the use of aspirin alone, the use of DAPT after bypass surgery was associated with less severe progression of native coronary stenoses and fewer new coronary occlusions. Native CAD often continues to increase in severity after CABG, leading to major adverse cardiac events. 10 A similar effect has been observed after PCI where, for instance, native CAD exacerbation in diabetic patients accounts for more major adverse cardiac events than target lesions as early as 18 months post-PCI. 15 Our hypothesis for this study was that DAPT may alleviate the process of native CAD progression, and knowing whether this effect exists may help choose optimal antiplatelet therapy after CABG. This secondary analysis of CASCADE trial is the first to address the effect of the addition of clopidogrel to aspirin on the progression of native CAD, in the context of a double-blinded, placebo-controlled randomized trial. We found no difference in the incidence of evolving or new CAD lesions 1 year after CABG between groups with and without the addition of clopidogrel to aspirin. However, among patients with evolving and new stenoses, the mean increase in lesion grade and the incidence of new occlusions were lower with aspirin plus clopidogrel compared with aspirin plus placebo.
Furthermore, in patients with DM, the mean grade change of evolving or new lesions was lower in the aspirin-clopidogrel group than in the aspirin-placebo group. This is relevant because diabetic patients are more susceptible to cardiovascular events as a result of endothelial, vascular smooth muscle cell, and platelet dysfunction. 16 Therefore, more careful prevention of atherosclerosis and atherothrombotic events is required in patients with DM after CABG.
For many years, the use of aspirin after CABG has been well supported (class Ia recommendation), and clopidogrel has been recommended only in patients with an allergy to aspirin (class IIa recommendation). 17, 18 Evidence for the use of DAPT after CABG has remained inconclusive. Recently, 2 meta-analysis studies showed that DAPT with aspirin and clopidogrel may improve early SVG patency and clinical outcomes, but not arterial graft patency after CABG. 19, 20 Furthermore, clopidogrel may work to prevent atherothrombotic events more effectively in off-pump CABG compared with on-pump CABG because of differences in platelet function early after surgery. 21, 22 The CASCADE randomized trial showed that there was no difference in SVG patency or the volume of SVG intimal hyperplasia between aspirin-clopidogrel and aspirin-placebo groups. 6 However, most operations were performed on-pump in the CASCADE trial (96%), and, as a corollary, it is conceivable that the effects of clopidogrel on native CAD progression could be more pronounced with off-pump CABG than what the present study showed.
One possible mechanism explaining the lower grade of stenotic changes in the aspirin-clopidogrel group is that there were fewer newly occluded lesions. Some studies reported that DAPT with aspirin and clopidogrel was more effective in preventing atherothrombotic events after acute coronary syndrome and PCI than aspirin alone. [1] [2] [3] In addition, previous animal studies indicate that clopidogrel may inhibit atherosclerosis. 4, 5 These implications may be important because large randomized trials recently showed that CABG is superior to PCI in patients with multivessel coronary disease. 23, 24 In those studies, many more patients were on DAPT in the PCI group than in the CABG group, and it is conceivable that DAPT after CABG might have further enhanced the benefits of CABG by limiting the magnitude of native CAD progression.
In this study, we also observed that most progression of CAD occurred in segments proximal to the graft anastomosis. This is consistent with previous studies 25 and may relate to the anatomic distribution of disease, as well as to turbulent flow, because of perfusion from the graft and the native coronary artery. The left coronary system was associated with less progression, and an arterial graft had a trend toward less progression. The high incidence of worsening CAD in the right coronary artery distribution may explain a higher incidence of graft failure in the late phase, potentially through a poorer and diminishing target perfusion area. In this regard, some studies have previously reported that the right coronary artery territory is a risk factor of SVG failure compared with grafting of the left coronary artery system. 26
Limitations
This was not an a priori planned secondary analysis of the CASCADE trial, and the findings should, therefore, be considered hypothesis generating. Other limitations of this study include those inherent to smaller studies, although the number of serially assessed lesions was relatively large at 543. Furthermore, the effects of clopidogrel on native CAD after CABG reported herein are based solely on angiographic data, and there was no significant difference in clinical outcomes between the 2 groups. The incidence of myocardial infarction was not statistically different between the treatment groups, although numerically higher in the aspirin-clopidogrel group (aspirin-clopidogrel versus aspirin-placebo group; 4 versus 1 patient; P=0.21). Perfusion imaging was not performed in the CASCADE trial. Overall, because the exacerbation of native CAD requires time, we think that long-term studies will be needed before observing differences in clinical outcomes or establishing causation. Other limitations of this study include the establishment of an arbitrary angiographic grading scale in the absence of an accepted gold standard for assessment of CAD progression after CABG. Furthermore, post hoc quantitative coronary angiogram was not used because of differences in hardware and imaging protocols between patients and centers. Finally, DAPT costs more than aspirin alone 27 and may lead to a higher risk of bleeding events, 19 which have to be considered against the subclinical benefits of its use observed in the present study.
Conclusions
Angiographic progression of native CAD is common after CABG and was found at 1 year in >70% of patients in the CASCADE randomized controlled trial. There was no difference in the proportion of patients with evolving or new native CAD lesions by 1 year after CABG, regardless of whether they took clopidogrel or placebo in addition to aspirin. Native CAD progression after CABG occurs most commonly in segments proximal rather than distal to a graft anastomosis and more often in the right rather than the left coronary system. When evolving or new native CAD lesions occurred, the use of clopidogrel plus aspirin was associated with significantly less severe worsening compared with the use of aspirin alone. These findings are novel, intriguing, and imply a potential role for the use of DAPT in limiting the extent of native coronary lesion worsening after CABG.
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